Dr. Balar talked about the keynote 057 study: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).
Read the overview on this study by Dr. Francesco Soria.